<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23442556</article-id><article-id pub-id-type="pmc">3598536</article-id><article-id pub-id-type="publisher-id">1471-2407-13-89</article-id><article-id pub-id-type="doi">10.1186/1471-2407-13-89</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>A randomised controlled trial of a mindfulness intervention for men with advanced prostate cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Chambers</surname><given-names>Suzanne K</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>suzanne.chambers@griffith.edu.au</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Smith</surname><given-names>David P</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>dsmith@nswcc.org.au</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Berry</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I6">6</xref><email>loncromb@gmail.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Lepore</surname><given-names>Stephen J</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>slepore@temple.edu</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Foley</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>elizabeth@mindpotential.com.au</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Clutton</surname><given-names>Samantha</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><email>samanthaclutton@cancerqld.org.au</email></contrib><contrib contrib-type="author" id="A7"><name><surname>McDowall</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><email>robmcdowall@cancerqld.org.au</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Occhipinti</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I9">9</xref><email>s.occhipinti@griffith.edu.au</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Frydenberg</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I10">10</xref><xref ref-type="aff" rid="I11">11</xref><email>frydenberg@optusnet.com.au</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Gardiner</surname><given-names>Robert A</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I12">12</xref><xref ref-type="aff" rid="I13">13</xref><email>f.gardiner@uq.edu.au</email></contrib></contrib-group><aff id="I1"><label>1</label>Griffith Health Institute, Griffith University, 4222, Gold Coast, QLD, Australia</aff><aff id="I2"><label>2</label>Cancer Council Queensland, Brisbane, Australia</aff><aff id="I3"><label>3</label>Prostate Cancer Foundation of Australia, Sydney, Australia</aff><aff id="I4"><label>4</label>Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, Australia</aff><aff id="I5"><label>5</label>Cancer Council NSW, Sydney, Australia</aff><aff id="I6"><label>6</label>University of New South Wales, Sydney, Australia</aff><aff id="I7"><label>7</label>Department of Public Health, Temple University, Philadelphia, USA</aff><aff id="I8"><label>8</label>Mind Potential, Sydney, Australia</aff><aff id="I9"><label>9</label>School of Psychology, Griffith University, Brisbane, Australia</aff><aff id="I10"><label>10</label>Department of Surgery, Monash University, Melbourne, Australia</aff><aff id="I11"><label>11</label>Royal Melbourne Hospital, Melbourne, Australia</aff><aff id="I12"><label>12</label>University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Australia</aff><aff id="I13"><label>13</label>Department of Urology, Royal Brisbane and Women’s Hospital, Brisbane, Australia</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>26</day><month>2</month><year>2013</year></pub-date><volume>13</volume><fpage>89</fpage><lpage>89</lpage><history><date date-type="received"><day>14</day><month>1</month><year>2013</year></date><date date-type="accepted"><day>21</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>Copyright ©2013 Chambers et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Chambers et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2407/13/89"></self-uri><abstract><sec><title><offsets xml_i="6028" xml_f="6038" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="6049" xml_f="6791" txt_i="22" txt_f="764">Prostate cancer is the most common male cancer in developed countries, and in Australia approximately one-fifth of men with prostate cancer have advanced disease. By comparison to men with localised prostate cancer, men with advanced disease report higher levels of psychological distress; poorer quality of life; and have an increased risk of suicide. To date no psychological intervention research specifically targeting men with advanced prostate cancer has been reported. In this paper we present the protocol of a current randomised controlled trial to assess the effectiveness of a professionally-led mindfulness-based cognitive therapy (MBCT) group intervention to improve psychological well-being in men with advanced prostate cancer.</offsets></p></sec><sec><title><offsets xml_i="6813" xml_f="6827" txt_i="766" txt_f="780">Methods/design</offsets></title><p><offsets xml_i="6838" xml_f="7771" txt_i="781" txt_f="1714">Ninety-five men per condition (190 men in total) will be recruited through clinicians in the Australian and New Zealand Urogenital and Prostate Cancer Trials Group and in major treatment centres in Queensland, New South Wales, Victoria and Western Australia. Patients are randomised to: (1) tele-based MBCT intervention or (2) patient education. A series of previously validated and reliable self-report measures will be administered to men at four time points: baseline/recruitment, and at 3, 6, and 9 months after recruitment and intervention commencement. Engagement with the principles of mindfulness and adherence to practice will be included as potential mediators of intervention effect. Primary outcomes are anxiety, depression and cancer-specific distress. Secondary outcomes are health-related quality of life (QoL) and benefit finding. Disease variables (e.g. cancer grade, stage) will be assessed through medical records.</offsets></p></sec><sec><title><offsets xml_i="7793" xml_f="7803" txt_i="1716" txt_f="1726">Discussion</offsets></title><p><offsets xml_i="7814" xml_f="8023" txt_i="1727" txt_f="1936">This study will address a critical but as yet unanswered research question: to identify an effective way to reduce psychological distress; and improve the quality of life for men with advanced prostate cancer.</offsets></p></sec><sec><title><offsets xml_i="8045" xml_f="8063" txt_i="1938" txt_f="1956">Trial registration</offsets></title><p><ext-link ext-link-type="uri" xlink:href="http://ACTRN12612000306819"><offsets xml_i="8144" xml_f="8170" txt_i="1957" txt_f="1983">http://ACTRN12612000306819</offsets></ext-link></p></sec></abstract><kwd-group><kwd>Prostate cancer</kwd><kwd>Randomised controlled trial (RCT)</kwd><kwd>Supportive care</kwd><kwd>Mental health</kwd><kwd>Psychological distress</kwd><kwd>Quality of life</kwd><kwd>Health outcomes</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="8471" xml_f="8481" txt_i="1992" txt_f="2002">Background</offsets></title><p><offsets xml_i="8492" xml_f="8668" txt_i="2003" txt_f="2179">Prostate cancer is the most common male cancer in developed countries (excluding non-melanoma skin cancer). In 2007, 19,403 Australian men were diagnosed with prostate cancer [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="8699" xml_f="8700" txt_i="2179" txt_f="2180">1</offsets></xref><offsets xml_i="8707" xml_f="8825" txt_i="2180" txt_f="2298">]. Approximately 10-15% of men with prostate cancer have locally advanced or metastatic prostate cancer at diagnosis [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="8856" xml_f="8857" txt_i="2298" txt_f="2299">2</offsets></xref><offsets xml_i="8864" xml_f="8983" txt_i="2299" txt_f="2418">] and a further 20-40% of men with localised cancer at diagnosis experience recurrence or progression after treatment [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="9014" xml_f="9015" txt_i="2418" txt_f="2419">3</offsets></xref><offsets xml_i="9022" xml_f="9320" txt_i="2419" txt_f="2717">]. Men with advanced prostate cancer face additional physical and psychological challenges compared to men with localised disease. The iatrogenic effects of hormonal ablation, the main treatment for advanced disease, include mood disturbance, cognitive impairment, fatigue, and sexual dysfunction [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="9351" xml_f="9352" txt_i="2717" txt_f="2718">4</offsets></xref><offsets xml_i="9359" xml_f="9522" txt_i="2718" txt_f="2881">]. By comparison to men with localised prostate cancer, men with advanced disease report higher levels of psychological distress and poorer quality of life (QoL) [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="9553" xml_f="9554" txt_i="2881" txt_f="2882">5</offsets></xref><offsets xml_i="9561" xml_f="9562" txt_i="2882" txt_f="2883">,</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="9593" xml_f="9594" txt_i="2883" txt_f="2884">6</offsets></xref><offsets xml_i="9601" xml_f="9643" txt_i="2884" txt_f="2926">]; and have an increased risk of suicide [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="9674" xml_f="9675" txt_i="2926" txt_f="2927">7</offsets></xref><offsets xml_i="9682" xml_f="9683" txt_i="2927" txt_f="2928">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="9714" xml_f="9715" txt_i="2928" txt_f="2929">8</offsets></xref><offsets xml_i="9722" xml_f="9834" txt_i="2929" txt_f="3041">]. Hence research into psychological intervention to maximise psychological adjustment is crucial for these men.</offsets></p><p><offsets xml_i="9841" xml_f="9965" txt_i="3042" txt_f="3166">To date, no psychological intervention research specifically targeting men with advanced prostate cancer has been reported [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="9996" xml_f="9997" txt_i="3166" txt_f="3167">9</offsets></xref><offsets xml_i="10004" xml_f="10737" txt_i="3167" txt_f="3900">]. In this study we propose using the cognitive behavioural approach of Mindfulness-Based Cognitive Therapy (MBCT) as relevant to this patient group. Mindfulness involves open awareness of current experience and the intention to observe habits of reacting to difficulties as they arise. Over time, this practice leads the person to gain the ability to be less reactive to difficult experiences and approach equanimity regarding the content of the illness experience, including negative emotions and thoughts. MBCT specifically targets the cognitive processes associated with depression by encouraging participants to disengage from reactive and ruminative states of mind, such as those that are commonly reported by cancer patients [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="10769" xml_f="10771" txt_i="3900" txt_f="3902">10</offsets></xref><offsets xml_i="10778" xml_f="10779" txt_i="3902" txt_f="3903">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="10811" xml_f="10813" txt_i="3903" txt_f="3905">11</offsets></xref><offsets xml_i="10820" xml_f="11059" txt_i="3905" txt_f="4144">]. Qualitative studies of cancer patients who have taken part in mindfulness courses have identified positive changes in acceptance, self-control, personal growth, shared experience and self-regulation as outcomes of mindfulness practice [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="11091" xml_f="11093" txt_i="4144" txt_f="4146">12</offsets></xref><offsets xml_i="11100" xml_f="11101" txt_i="4146" txt_f="4147">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="11133" xml_f="11135" txt_i="4147" txt_f="4149">13</offsets></xref><offsets xml_i="11142" xml_f="11322" txt_i="4149" txt_f="4329">]. In a pilot study of group MBCT conducted with 19 men with advanced prostate cancer, men reported significant changes in both general psychological and cancer-specific distress [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="11354" xml_f="11356" txt_i="4329" txt_f="4331">14</offsets></xref><offsets xml_i="11363" xml_f="11684" txt_i="4331" txt_f="4652">]. Qualitative data revealed that acceptance of and learning from other group members were key aspects of the group context that contributed to acceptance of progressive disease. Thus, in the context of MBCT the group setting appears important as a contributor to acceptance of cancer through peer learning and modelling.</offsets></p><p><offsets xml_i="11691" xml_f="11865" txt_i="4653" txt_f="4827">Accordingly, in this trial we apply a tele-based MBCT group intervention to decrease anxiety and depression and cancer-specific distress in men with advanced prostate cancer.</offsets></p></sec><sec><title><offsets xml_i="11887" xml_f="11901" txt_i="4829" txt_f="4843">Methods/design</offsets></title><p><offsets xml_i="11912" xml_f="12025" txt_i="4844" txt_f="4957">The study has two arms: 1) MBCT delivered by teleconference over eight weekly sessions and (2) patient education.</offsets></p><p><offsets xml_i="12032" xml_f="12129" txt_i="4958" txt_f="5055">It is hypothesised that 3, 6 and 9 months after recruitment and commencement of the intervention:</offsets></p><p><offsets xml_i="12136" xml_f="12246" txt_i="5056" txt_f="5166">1. Relative to men who receive patient education, men who receive MBCT will have lower anxiety and depression.</offsets></p><p><offsets xml_i="12253" xml_f="12365" txt_i="5167" txt_f="5279">2. Relative to men who receive patient education, men who receive MBCT will have lower cancer-specific distress.</offsets></p><p><offsets xml_i="12372" xml_f="12472" txt_i="5280" txt_f="5380">3. Relative to men who receive patient education, men who receive MBCT will have higher mindfulness.</offsets></p><p><offsets xml_i="12479" xml_f="12580" txt_i="5381" txt_f="5482">4. Intervention-driven improvements in psychological outcomes will be mediated by mindfulness skills.</offsets></p><sec><title><offsets xml_i="12596" xml_f="12611" txt_i="5483" txt_f="5498">Group condition</offsets></title><sec><title><italic><offsets xml_i="12639" xml_f="12656" txt_i="5499" txt_f="5516">Patient Education</offsets></italic></title><p><offsets xml_i="12676" xml_f="12821" txt_i="5517" txt_f="5662">Patient education consists of the man’s standard medical management and a package containing existing evidence-based patient education materials.</offsets></p></sec><sec><title><italic><offsets xml_i="12851" xml_f="12886" txt_i="5664" txt_f="5699">Mindfulness-Based Cognitive Therapy</offsets></italic></title><p><offsets xml_i="12906" xml_f="13046" txt_i="5700" txt_f="5840">The Mindfulness-Based Cognitive Therapy group intervention (MBCT) follows a cancer-specific manual based on Segal, Williams and Teasdale’s [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="13078" xml_f="13080" txt_i="5840" txt_f="5842">15</offsets></xref><offsets xml_i="13087" xml_f="13205" txt_i="5842" txt_f="5960">] manual for MBCT, with novel specific components developed for men with advanced prostate cancer in our pilot study [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="13237" xml_f="13239" txt_i="5960" txt_f="5962">14</offsets></xref><offsets xml_i="13246" xml_f="14564" txt_i="5962" txt_f="7280">]. The sessions are facilitated by health professionals with experience in oncology and professional training in MBCT. The program has been further developed to be suitable for telephone delivery. For example, facilitators have been trained to use explicit communication such as encouraging group members to say their name before contributing, listen closely to the tone of participants' voices, give extra time for responses, and have explicit rules for how the group will interact. Each session runs for 1.25-h and only short (up to 15 min) meditations are provided during the group phone sessions to support group engagement and alleviate practical concerns such as holding the telephone receiver. As well, the material in participant workbooks has been elaborated to provide session plans, so participants can navigate phone sessions more easily, and interactive worksheets are provided to help keep group discussions on task. The program includes eight weekly group teleconferences, and each participant has an individual introductory call with their facilitator to allow them to connect with the facilitator, prepare them for the program and to enhance motivation. Participants are provided with a handbook summarising each weekly session; self-help materials including Jon Kabat Zinn’s Full Catastrophe Living [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="14596" xml_f="14598" txt_i="7280" txt_f="7282">16</offsets></xref><offsets xml_i="14605" xml_f="15136" txt_i="7282" txt_f="7813">]; and an audio recorded meditation on compact disc. Daily home practice of mindfulness meditation is strongly encouraged; with participants asked to engage in one of the four 35 min practices depending on the stage of the course (the body scan, moving meditation, mixed mindfulness meditation, silent practice with bells at 5 min intervals). Finally, as in our pilot study, peer interaction is directed towards support for the learning of mindfulness skills and mutual support in facing the challenges of advanced prostate cancer.</offsets></p></sec></sec><sec><title><offsets xml_i="15164" xml_f="15176" txt_i="7816" txt_f="7828">Participants</offsets></title><p><offsets xml_i="15187" xml_f="15659" txt_i="7829" txt_f="8301">Recruitment is being undertaken through clinicians in the Australian and New Zealand Urogenital and Prostate Cancer Trials Group and in major treatment centres in Queensland, New South Wales, Victoria and Western Australia. Other recruitment avenues include the distribution of information through prostate cancer support groups and media promotion. The research team who contact potential participants after referral to the study obtains informed written consent. Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="15689" xml_f="15690" txt_i="8301" txt_f="8302">1</offsets></xref><offsets xml_i="15697" xml_f="15768" txt_i="8302" txt_f="8373"> illustrates the recruitment, intervention and data collection process.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="15809" xml_f="15817" txt_i="8374" txt_f="8382">Figure 1</offsets></label><caption><p><offsets xml_i="15837" xml_f="15891" txt_i="8382" txt_f="8436">Flowchart of recruitment, intervention and assessment.</offsets></p></caption><graphic xlink:href="1471-2407-13-89-1"></graphic></fig><p><offsets xml_i="15964" xml_f="16041" txt_i="8437" txt_f="8514">Inclusion criteria are that the men must: (1) have proven metastatic disease </offsets><italic><offsets xml_i="16049" xml_f="16051" txt_i="8514" txt_f="8516">or</offsets></italic><offsets xml_i="16060" xml_f="16283" txt_i="8516" txt_f="8739"> castration resistant biochemical progression; (2) be able to read and speak English; (3) have no previous history of head injury, dementia or psychiatric illness; (4) have no other concurrent cancer; (5) have phone access.</offsets></p><p><offsets xml_i="16290" xml_f="16559" txt_i="8740" txt_f="9009">Approximately 190 men will be recruited to the study (allowing 30% attrition from treatment; 65 men in each condition will complete final assessments). This sample size would comfortably exceed 80% power to detect a moderate to large effect over four assessment points.</offsets></p></sec><sec><title><offsets xml_i="16581" xml_f="16596" txt_i="9011" txt_f="9026">Study integrity</offsets></title><p><offsets xml_i="16607" xml_f="16880" txt_i="9027" txt_f="9300">Ethical approval has been obtained from the Griffith University Human Research Ethics Committee (Approval: PSY/15/12/HREC) and Metro-North – The Prince Charles Hospital Human Research Ethics Committee (HREC/12/QPCH/101). The study design is guided by the CONSORT criteria [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="16912" xml_f="16914" txt_i="9300" txt_f="9302">17</offsets></xref><offsets xml_i="16921" xml_f="17853" txt_i="9302" txt_f="10234">]. Randomisation to study condition occurs following the completion of baseline assessment. Assessments are by self-report pen and paper measures and project staff tracking assessments are blinded to condition where possible. Randomisation occurs in blocks of 14, with each condition randomly generated 7 times within each block to ensure an unpredictable allocation sequence with equal numbers of men in each condition at the completion of each block; and sufficient men to form a tele-based group (of 7) in the MBCT condition. Randomisation occurs within Queensland-Western Australia and New South Wales-Victoria dyads to coincide with a two-stage commencement of recruitment. The randomisation sequence is undertaken by the project manager and concealed from investigators. The group sessions are audiotaped with 15% reviewed to ensure adherence to an MBCT approach. Analyses will be conducted on the basis of intention to treat.</offsets></p></sec><sec><title><offsets xml_i="17875" xml_f="17883" txt_i="10236" txt_f="10244">Measures</offsets></title><p><offsets xml_i="17894" xml_f="18452" txt_i="10245" txt_f="10803">A series of previously validated and reliable self-report measures are administered by mail to men at four time points: baseline/recruitment and at 3, 6, and 9 months after recruitment and intervention commencement. Mindfulness skills are included as potential mediators of intervention effect. Primary outcomes are anxiety, depression and cancer-specific distress. Secondary outcomes are global QoL and benefit finding. Disease variables (e.g. cancer grade, stage, time since diagnosis, time since treatment) will be assessed through medical records review.</offsets></p><sec><title><offsets xml_i="18468" xml_f="18477" txt_i="10804" txt_f="10813">Mediators</offsets></title><p><offsets xml_i="18488" xml_f="18550" txt_i="10814" txt_f="10876">Mindfulness: The Five Facet Mindfulness Questionnaire (FFMQ) [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="18582" xml_f="18584" txt_i="10876" txt_f="10878">18</offsets></xref><offsets xml_i="18591" xml_f="18682" txt_i="10878" txt_f="10969">] is being used to measure the participants’ engagement with the principles of mindfulness.</offsets></p><p><offsets xml_i="18689" xml_f="18812" txt_i="10970" txt_f="11093">Adherence to Practice: Adherence to mindfulness practice is assessed by participants completing a daily home practice form.</offsets></p></sec><sec><title><offsets xml_i="18834" xml_f="18859" txt_i="11095" txt_f="11120">Primary outcome variables</offsets></title><p><offsets xml_i="18870" xml_f="18926" txt_i="11121" txt_f="11177">Anxiety and Depression: The Brief Symptom Inventory-18 [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="18958" xml_f="18960" txt_i="11177" txt_f="11179">19</offsets></xref><offsets xml_i="18967" xml_f="19096" txt_i="11179" txt_f="11308">] is providing a global measure of current psychological distress with subscale scores for anxiety, depression, and somatisation.</offsets></p><p><offsets xml_i="19103" xml_f="19163" txt_i="11309" txt_f="11369">Cancer-Specific Distress: The Impact of Events Scale (IES) [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="19195" xml_f="19197" txt_i="11369" txt_f="11371">20</offsets></xref><offsets xml_i="19204" xml_f="19205" txt_i="11371" txt_f="11372">,</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="19237" xml_f="19239" txt_i="11372" txt_f="11374">21</offsets></xref><offsets xml_i="19246" xml_f="19337" txt_i="11374" txt_f="11465">] and the PSA Anxiety subscale of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="19369" xml_f="19371" txt_i="11465" txt_f="11467">22</offsets></xref><offsets xml_i="19378" xml_f="19436" txt_i="11467" txt_f="11525">] is being used to measure men’s cancer-specific distress.</offsets></p></sec><sec><title><offsets xml_i="19458" xml_f="19485" txt_i="11527" txt_f="11554">Secondary outcome variables</offsets></title><p><offsets xml_i="19496" xml_f="19578" txt_i="11555" txt_f="11637">Quality of Life: The Functional Assessment of Cancer Therapy – Prostate (FACT-P) [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="19610" xml_f="19612" txt_i="11637" txt_f="11639">23</offsets></xref><offsets xml_i="19619" xml_f="19803" txt_i="11639" txt_f="11823">] is being used to assess the men’s perceived global quality of life across 5 domains: physical, social/family, emotional, functional well-being, and prostate cancer-specific concerns.</offsets></p><p><offsets xml_i="19810" xml_f="19981" txt_i="11824" txt_f="11995">Benefit Finding: Positive adjustment is being measured with the Posttraumatic Growth Inventory assessing perceived positive outcomes resulting from a diagnosis of cancer [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="20013" xml_f="20015" txt_i="11995" txt_f="11997">24</offsets></xref><offsets xml_i="20022" xml_f="20024" txt_i="11997" txt_f="11999">].</offsets></p></sec></sec><sec><title><offsets xml_i="20052" xml_f="20072" txt_i="12002" txt_f="12022">Statistical analyses</offsets></title><p><offsets xml_i="20083" xml_f="21150" txt_i="12023" txt_f="13090">The study is a two-condition randomised controlled trial with repeated measures across time and continuous outcome variables. The analysis of longitudinal differences in outcome will be by multilevel (mixed) modelling (MLM). These procedures allow the testing of typical group level predictions such as Hypotheses 1 to 3 that men in the intervention condition will have better outcomes than the patient education group. However, by incorporating the hierarchical structure of assessment points nested within individual men they further permit the true assessment of individual change in psychological outcomes and of potential mediators of such change (Hypothesis 4). Consequently (and unlike traditional approaches), this model deals with the heterogeneity of responses, such as that expected in the outcomes of the proposed study, by allowing such variation as random effects within the model. MLM has the advantage of allowing use of all available data points, which maximizes power to detect effects and reduces bias owing to missing data in longitudinal studies.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="21200" xml_f="21210" txt_i="13093" txt_f="13103">Discussion</offsets></title><p><offsets xml_i="21221" xml_f="21607" txt_i="13104" txt_f="13490">The study will provide recommendations about effective psychological interventions to reduce anxiety, depression and cancer-specific distress in men with advanced prostate cancer. To our knowledge, to date no psychological intervention studies have targeted men with advanced prostate cancer specifically; or trialled remotely delivered mindfulness interventions in cancer populations [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="21638" xml_f="21639" txt_i="13490" txt_f="13491">9</offsets></xref><offsets xml_i="21646" xml_f="22083" txt_i="13491" txt_f="13928">]. This research will overcome these limitations. If proven effective, the intervention will be able to be utilised in a range of settings including broad reach tele-health support programs; and through support services and support groups internationally. This means that project outputs will be immediately translatable into practice to reduce psychological distress and improve the quality of life of men with advanced prostate cancer.</offsets></p></sec><sec><title><offsets xml_i="22105" xml_f="22124" txt_i="13930" txt_f="13949">Competing interests</offsets></title><p><offsets xml_i="22135" xml_f="22193" txt_i="13950" txt_f="14008">The authors declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="22215" xml_f="22237" txt_i="14010" txt_f="14032">Authors’ contributions</offsets></title><p><offsets xml_i="22248" xml_f="22595" txt_i="14033" txt_f="14380">SKC, DS and MB developed the study concept and aims and initiated the project. SL, EF, SC, RM, SO, MF and RAG assisted in further development of the protocol. SKC was responsible for drafting the manuscript. SKC, DS, EF, SC, RM and SO will implement the protocol and oversee collection of the data. All authors contributed to the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="22617" xml_f="22640" txt_i="14382" txt_f="14405">Pre-publication history</offsets></title><p><offsets xml_i="22651" xml_f="22715" txt_i="14406" txt_f="14470">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/13/89/prepub"><offsets xml_i="22817" xml_f="22868" txt_i="14471" txt_f="14522">http://www.biomedcentral.com/1471-2407/13/89/prepub</offsets></ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>This project was funded by the Australian National Health and Medical Research Council (ID APP1024989), and undertaken in partnership with the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group and Cancer Council Queensland and New South Wales. We gratefully acknowledge the support of the Prostate Cancer Foundation of Australia; the Urological Society of Australia and New Zealand; of Professor Ian Davis, Dr Peter Heathcote, Professor Nigel Spry, Associate Professor Martin Stockler, and Dr John Yaxley as associate investigators; and of Mr Bill McHugh and Mr Peter Dornan as consumer advisors.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="book"><collab>Australian Institute of Health and Welfare, Australasian Association of Cancer Registries</collab><source>Cancer in Australia: An overview, 2006</source><series>Cancer Series AIHW cat no CAN 32</series><year>2007</year><publisher-name>Canberra: Australian Institute of Health and Welfare</publisher-name></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="book"><name><surname>Alam</surname><given-names>N</given-names></name><name><surname>You</surname><given-names>H</given-names></name><name><surname>Banks</surname><given-names>C</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Bishop</surname><given-names>J</given-names></name><source>
Prostate Cancer in New South Wales
</source><year>2009</year><publisher-name>Sydney: Cancer Institute NSW</publisher-name></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Partin</surname><given-names>AW</given-names></name><name><surname>Zahurak</surname><given-names>M</given-names></name><name><surname>Piantadosi</surname><given-names>S</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name><name><surname>Walsh</surname><given-names>PC</given-names></name><article-title>Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer</article-title><source>J Urol</source><year>2003</year><volume>169</volume><issue>2</issue><fpage>517</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(05)63946-8</pub-id><pub-id pub-id-type="pmid">12544300</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="book"><collab>Australian Cancer Network Management of Metastatic Prostate Cancer Working Party</collab><source>Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer</source><year>2010</year><publisher-name>Sydney: Cancer Council Australia and Australian Cancer Network</publisher-name></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Eton</surname><given-names>DT</given-names></name><name><surname>Lepore</surname><given-names>SJ</given-names></name><article-title>Prostate cancer and health-related quality of life: a review of the literature</article-title><source>Psychooncology</source><year>2002</year><volume>11</volume><issue>4</issue><fpage>307</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1002/pon.572</pub-id><pub-id pub-id-type="pmid">12203744</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Bloch</surname><given-names>S</given-names></name><name><surname>Love</surname><given-names>A</given-names></name><name><surname>Macvean</surname><given-names>M</given-names></name><name><surname>Duchesne</surname><given-names>G</given-names></name><name><surname>Couper</surname><given-names>J</given-names></name><name><surname>Kissane</surname><given-names>D</given-names></name><article-title>Psychological adjustment of men with prostate cancer: a review of the literature</article-title><source>Biopsychosoc Med</source><year>2007</year><volume>1</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1751-0759-1-2</pub-id><pub-id pub-id-type="pmid">17371571</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Bill-Axelson</surname><given-names>A</given-names></name><name><surname>Garmo</surname><given-names>H</given-names></name><name><surname>Lambe</surname><given-names>M</given-names></name><name><surname>Bratt</surname><given-names>O</given-names></name><name><surname>Adolfsson</surname><given-names>J</given-names></name><name><surname>Nyberg</surname><given-names>U</given-names></name><name><surname>Steineck</surname><given-names>G</given-names></name><name><surname>Stattin</surname><given-names>P</given-names></name><article-title>Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden</article-title><source>Eur Urol</source><year>2010</year><volume>57</volume><issue>3</issue><fpage>390</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2009.10.035</pub-id><pub-id pub-id-type="pmid">19914773</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Keating</surname><given-names>NL</given-names></name><name><surname>Mucci</surname><given-names>LA</given-names></name><name><surname>Adami</surname><given-names>H</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Valdimarsdottir</surname><given-names>U</given-names></name><name><surname>Fall</surname><given-names>K</given-names></name><article-title>Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States</article-title><source>J Natl Cancer Inst</source><year>2010</year><volume>102</volume><issue>5</issue><fpage>307</fpage><pub-id pub-id-type="doi">10.1093/jnci/djp537</pub-id><pub-id pub-id-type="pmid">20124521</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Chambers</surname><given-names>SK</given-names></name><name><surname>Pinnock</surname><given-names>C</given-names></name><name><surname>Lepore</surname><given-names>SJ</given-names></name><name><surname>Hughes</surname><given-names>S</given-names></name><name><surname>O'Connell</surname><given-names>DL</given-names></name><article-title>A systematic review of psychosocial interventions for men with prostate cancer and their partners</article-title><source>Patient Educ Couns</source><year>2011</year><volume>85</volume><issue>2</issue><fpage>e75</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.pec.2011.01.027</pub-id><pub-id pub-id-type="pmid">21334159</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Lau</surname><given-names>MA</given-names></name><name><surname>Segal</surname><given-names>ZV</given-names></name><name><surname>Williams</surname><given-names>JMG</given-names></name><article-title>Teasdale’s differential activation hypothesis: implications for mechanisms of depressive relapse and suicidal behaviour</article-title><source>Behav Res Ther</source><year>2004</year><volume>42</volume><fpage>1001</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1016/j.brat.2004.03.003</pub-id><pub-id pub-id-type="pmid">15325898</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Sheppard</surname><given-names>LC</given-names></name><name><surname>Teasdale</surname><given-names>JD</given-names></name><article-title>How does dysfunctional thinking decrease during recovery from major depression?</article-title><source>J Abnorm Psychol</source><year>2004</year><volume>113</volume><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">14992658</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Dobkin</surname><given-names>PL</given-names></name><article-title>Mindfulness-based stress reduction: what processes are at work?</article-title><source>Complement Ther Clin Pract</source><year>2008</year><volume>14</volume><issue>1</issue><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ctcp.2007.09.004</pub-id><pub-id pub-id-type="pmid">18243937</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>McKenzie</surname><given-names>MJ</given-names></name><name><surname>Carlson</surname><given-names>LE</given-names></name><name><surname>Munoz</surname><given-names>M</given-names></name><name><surname>Speca</surname><given-names>M</given-names></name><article-title>A qualitative study of self perceived effects of mindfulness based stress reduction in a psychosocial oncology setting</article-title><source>Stress and Health</source><year>2007</year><volume>23</volume><issue>1</issue><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1002/smi.1120</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Chambers</surname><given-names>SK</given-names></name><name><surname>Foley</surname><given-names>E</given-names></name><name><surname>Galt</surname><given-names>E</given-names></name><name><surname>Ferguson</surname><given-names>M</given-names></name><name><surname>Clutton</surname><given-names>S</given-names></name><article-title></article-title><source>Support Care Cancer</source><year>2012</year><volume>20</volume><issue>6</issue><fpage>1183</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1007/s00520-011-1195-8</pub-id><pub-id pub-id-type="pmid">21625914</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="book"><name><surname>Segal</surname><given-names>ZV</given-names></name><name><surname>Williams</surname><given-names>JMG</given-names></name><name><surname>Teasdale</surname><given-names>JD</given-names></name><source>Mindfulness-based cognitive therapy for depression: a new approach to preventing relapse</source><year>2002</year><publisher-name>New York: Guilford Press</publisher-name></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="book"><name><surname>Kabat-Zinn</surname><given-names>J</given-names></name><source>Full catastrophe living: using the wisdom of your body and mind to face stress, pain, and illness</source><year>1990</year><publisher-name>New York: Delacorte</publisher-name></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><article-title>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</article-title><source>BMC Med</source><year>2010</year><volume>8</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/1741-7015-8-18</pub-id><pub-id pub-id-type="pmid">20334633</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Baer</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>GT</given-names></name><name><surname>Hopkins</surname><given-names>J</given-names></name><name><surname>Krietemeyer</surname><given-names>J</given-names></name><name><surname>Toney</surname><given-names>L</given-names></name><article-title>Using self-report assessment methods to explore facets of mindfulness</article-title><source>Assessment</source><year>2006</year><volume>13</volume><issue>1</issue><fpage>27</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1177/1073191105283504</pub-id><pub-id pub-id-type="pmid">16443717</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="book"><name><surname>Derogatis</surname><given-names>LR</given-names></name><source>BSI-18: Administration, Scoring and Procedures Manual</source><year>2000</year><publisher-name>Minneappolis MN: National Computer Systems</publisher-name></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Wilner</surname><given-names>N</given-names></name><name><surname>Alvarez</surname><given-names>W</given-names></name><article-title>Impact of event scale: a measure of subjective stress</article-title><source>Psychosom Med</source><year>1979</year><volume>41</volume><issue>3</issue><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">472086</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="book"><name><surname>Weiss</surname><given-names>DS</given-names></name><name><surname>Marmar</surname><given-names>CR</given-names></name><person-group person-group-type="editor">Wilson JP, Keane TM</person-group><article-title>The Impact of Events Scale - Revised</article-title><source>Assessing Psychological Trauma and PTSD</source><year>1997</year><publisher-name>New York: Guilford Press</publisher-name><fpage>399</fpage><lpage>411</lpage></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Roth</surname><given-names>AJ</given-names></name><name><surname>Rosenfeld</surname><given-names>B</given-names></name><name><surname>Kornblith</surname><given-names>AB</given-names></name><name><surname>Gibson</surname><given-names>C</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Curley-Smart</surname><given-names>T</given-names></name><name><surname>Holland</surname><given-names>JC</given-names></name><name><surname>Breitbart</surname><given-names>W</given-names></name><article-title>The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with prostate cancer</article-title><source>Cancer</source><year>2003</year><volume>97</volume><issue>11</issue><fpage>2910</fpage><lpage>2918</lpage><pub-id pub-id-type="doi">10.1002/cncr.11386</pub-id><pub-id pub-id-type="pmid">12767107</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Cella</surname><given-names>DF</given-names></name><name><surname>Tulsky</surname><given-names>DS</given-names></name><name><surname>Gray</surname><given-names>G</given-names></name><name><surname>Sarafian</surname><given-names>B</given-names></name><name><surname>Linn</surname><given-names>E</given-names></name><name><surname>Bonomi</surname><given-names>A</given-names></name><name><surname>Silberman</surname><given-names>M</given-names></name><name><surname>Yellen</surname><given-names>SB</given-names></name><name><surname>Winicour</surname><given-names>P</given-names></name><name><surname>Brannon</surname><given-names>J</given-names></name><article-title>The functional assessment of cancer therapy scale: development and validation of the general measure</article-title><source>J Clin Oncol</source><year>1993</year><volume>11</volume><issue>3</issue><fpage>570</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">8445433</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Tedeschi</surname><given-names>RG</given-names></name><name><surname>Calhoun</surname><given-names>LG</given-names></name><article-title>The posttraumatic growth inventory: measuring the positive legacy of trauma</article-title><source>J Trauma Stress</source><year>1996</year><volume>9</volume><issue>3</issue><fpage>455</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1002/jts.2490090305</pub-id><pub-id pub-id-type="pmid">8827649</pub-id></mixed-citation></ref></ref-list></back></article>